Systemic treatment of a human epidermoid non-small cell lung carcinoma xenograft with a xanthate compound causes extensive intratumoral necrosis.
Therapeutic effects were obtained after systemic treatment of athymic mice bearing an epidermoid non-small cell human lung carcinoma (NSCLC) xenograft with tricyclodecan-9-yl xanthogenate (D609) and the potassium salt of a fatty (dodecanoic) acid. Extensive intratumoral necrosis was observed 3 days after the treatment.
Sauer
G
G
Institute for Virus Research, German Cancer Research Center, Heidelberg.
Amtmann
E
E
Hofmann
W
W
D000818:Animals; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations; D006801:Humans; D007850:Lauric Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009336:Necrosis; D009368:Neoplasm Transplantation; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D004338:Drug Combinations; D007850:Lauric Acids; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones; C030358:lauric acid; C046498:tricyclodecane-9-yl-xanthogenate